PB2426: SORAFENIB MAINTENANCE TAILORED TO FLT3-MUTATED AML AFTER ALLOGENEIC HCT IS HIGHLY FEASIBLE AND EFFECTIVE: A REAL-LIFE EXPERIENCE

PB2426: SORAFENIB MAINTENANCE TAILORED TO FLT3-MUTATED AML AFTER ALLOGENEIC HCT IS HIGHLY FEASIBLE AND EFFECTIVE: A REAL-LIFE EXPERIENCE

Bibliographic Details
Main Authors:	Elisa Diral, Giulia Furnari, Francesca Farina, Daniela Clerici, Sarah Marktel, Raffaella Greco, Gloria Catalano, Alessandro Bruno, Edoardo Campodonico, Elisabetta Xue, Sara Mastaglio, Luca Vago, Massimo Stefano Luca Bernardi, Matteo Giovanni Carrabba, Consuelo Corti, Jacopo Peccatori, Fabio Ciceri, Maria Teresa Lupo Stanghellini
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000976412.08733.1f

Similar Items

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
by: Massimo Bernardi, et al.
Published: (2022-07-01)

Leukoreductive response to the combination of sorafenib and chemotherapy in hyperleukocytosis of FLT3-ITD mutated pediatric AML
by: Franziska Schmidt, et al.
Published: (2022-11-01)

P1549: HIGH PREVALENCE OF RESPIRATORY SYNCYTIAL VIRUS IN HAEMATOLOGICAL PATIENTS AFTER COVID19 WAVES.
by: Francesca Farina, et al.
Published: (2023-08-01)

Second Solid Cancers After Hematopoietic Stem Cell Transplantation: Active Surveillance During Long-term Follow-up
by: Maria Teresa Lupo-Stanghellini, et al.
Published: (2021-11-01)

P1572: COVID-19 MORTALITY IN HIGH-RISK PATIENTS AFTER ALLO-HSCT AND CAR-T: IMPROVED OUTCOME THROUGH A PANDEMIC.
by: Daniele Sannipoli, et al.
Published: (2023-08-01)

Maintenance therapy for AML after allogeneic HCT
by: Rahul K. Nayak, et al.
Published: (2022-08-01)

Case Report: Invasive Fungal Infection and Daratumumab: A Case Series and Review of Literature
by: Francesca Farina, et al.
Published: (2022-07-01)

Role of Biomarkers in FLT3 AML
by: Nitika, et al.
Published: (2022-02-01)

P1319: TREATMENT WITH MIDOSTAURIN AND OTHER FLT3 TARGETING INHIBITORS IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH FLT3 MUTATED AML WHO UNDERWENT ALLOGENEIC HCT
by: Anjali Cremer, et al.
Published: (2023-08-01)

PB2575: HIGH INCIDENCE OF RESPIRATORY TRACT INFECTIONS FOLLOWING COVID-19 WAVES IN PATIENTS WITH PLASMA CELL DYSCRASIAS
by: Francesca Farina, et al.
Published: (2023-08-01)

Addition of a Single Low Dose of Anti T-Lymphocyte Globulin to Post-Transplant Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplant: A Pilot Study
by: Elisabetta Xue, et al.
Published: (2022-02-01)

MOLECULAR INTERNATIONAL PROGNOSTIC SCORING SYSTEM FOR MYELODYSPLASTIC SYNDROMES: A MONOCENTRIC EXPERIENCE
by: E. Diral, et al.
Published: (2024-01-01)

A Review of FLT3 Kinase Inhibitors in AML
by: Cristina Negotei, et al.
Published: (2023-10-01)

Nanosphere's Verigene® Blood Culture Assay to Detect Multidrug-Resistant Gram-Negative Bacterial Outbreak: A Prospective Study on 79 Hematological Patients in a Country with High Prevalence of Antimicrobial Resistance
by: Raffaella Greco, et al.
Published: (2019-06-01)

L45N C30 (24,26-30) [fotograf udara]

2426 Fostering cross-disciplinary research: Lessons learned from STTEP-UP
by: Hannibal Person, et al.
Published: (2018-06-01)

Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors
by: Nicholas J. Short, et al.
Published: (2023-09-01)

Real-world experience of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for FLT3-ITD AML reveals high rates of toxicity-related treatment interruption
by: Sarah Morin, et al.
Published: (2023-03-01)

Natural Flt3Lg-Based Chimeric Antigen Receptor (Flt3-CAR) T Cells Successfully Target Flt3 on AML Cell Lines
by: Varvara Maiorova, et al.
Published: (2021-10-01)

Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
by: Mark C Weir, et al.
Published: (2017-01-01)

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
by: Musa Yilmaz, et al.
Published: (2022-05-01)

FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review
by: Michael Loschi, et al.
Published: (2021-05-01)

AD80 HAS HIGHER POTENCY COMPARED TO CLINICALLY USED FLT3 INHIBITORS IN FLT3-ITD AML CELLS
by: LBL Miranda, et al.
Published: (2023-10-01)

Breakthrough Invasive Fungal Infections in Allogeneic Hematopoietic Stem Cell Transplantation
by: Carmine Liberatore, et al.
Published: (2021-04-01)

Mutated Flt3Lg Provides Reduced Flt3 Recycling Compared to Wild-Type Flt3Lg and Retains the Specificity of Flt3Lg-Based CAR T-Cell Targeting in AML Models
by: Varvara Maiorova, et al.
Published: (2023-04-01)

Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1
by: Daniel J.L. Coleman, et al.
Published: (2024-04-01)

CXCR4 Inhibition Enhances Efficacy of FLT3 Inhibitors in FLT3-Mutated AML Augmented by Suppressed TGF-β Signaling
by: Bo-Reum Kim, et al.
Published: (2020-06-01)

Terror-related injuries in Somalia: a retrospective cohort of 2426 hospitalized cases along 7 years
by: Ebubekir Arslan, et al.
Published: (2022-10-01)

ROLE OF BIALLELIC C/EBPALPHA MUTATIONS AND FLT-3 ITD IN INITIATION AND MAINTENANCE OF AML
by: Reckzeh, K, et al.
Published: (2010)

Unveiling the signaling network of FLT3-ITD AML improves drug sensitivity prediction
by: Sara Latini, et al.
Published: (2024-04-01)

Phosphoproteomic Characterization of Primary AML Samples and Relevance for Response Toward FLT3-inhibitors
by: David G. J. Cucchi, et al.
Published: (2021-07-01)

Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies for Treatment of AML
by: Maya Graham Pedersen, et al.
Published: (2022-09-01)

High-Risk Neutropenic Fever and Invasive Fungal Diseases in Patients with Hematological Malignancies
by: Giovanni Mori, et al.
Published: (2024-01-01)

Case report: Ponatinib as a bridge to CAR-T cells and subsequent maintenance in a patient with relapsed/refractory Philadelphia-like acute lymphoblastic leukemia
by: Fabio Giglio, et al.
Published: (2023-01-01)

Shift of N-MYC Oncogene Expression in AML Patients Carrying the FLT3-ITD Mutation
by: Konstantin Bogdanov, et al.
Published: (2023-08-01)

Aberrant Bone Homeostasis in AML Is Associated with Activated Oncogenic FLT3-Dependent Cytokine Networks
by: Isabel Bär, et al.
Published: (2020-11-01)

Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML
by: Lindblad, O, et al.
Published: (2017)

S126: GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. RESULTS FROM THE NCRI AML19 “MIDOTARG” PILOT TRIAL
by: N. Russell, et al.
Published: (2022-06-01)

P445: A SYSTEMS-BASED APPROACH TO UNVEIL DRUG RESISTANCE IN FLT3-ITD AML
by: Francesca Sacco, et al.
Published: (2023-08-01)

19S Proteasome Subunits as Oncogenes and Prognostic Biomarkers in FLT3-Mutated Acute Myeloid Leukemia (AML)
by: Joshua J. Lara, et al.
Published: (2022-11-01)